{"id":"NCT00113763","sponsor":"Amgen","briefTitle":"Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer","officialTitle":"An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-01-01","primaryCompletion":"2008-10-01","completion":"2009-06-01","firstPosted":"2005-06-13","resultsPosted":"2014-01-03","lastUpdate":"2022-11-07"},"enrollment":463,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer","Metastases"],"interventions":[{"type":"OTHER","name":"Best supportive care","otherNames":[]},{"type":"DRUG","name":"Panitumumab","otherNames":["ABX-EGF"]}],"arms":[{"label":"Panitumumab plus best supportive care","type":"EXPERIMENTAL"},{"label":"Best Supportive Care","type":"OTHER"}],"summary":"The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy).","primaryOutcome":{"measure":"Progression-free Survival Time","timeFrame":"From randomization to the data cut-off date of 30 June 2005. The median follow-up time was 20.0 weeks in the panitumumab plus BSC group and 18.2 weeks in the BSC alone group.","effectByArm":[{"arm":"Panitumumab Plus BSC","deltaMin":8,"sd":null},{"arm":"BSC Alone","deltaMin":7.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21448748","21190026","19189371","18040272","17470858","37596461","34213592","29627309","26049686","23625191","18316791"],"seeAlso":["http://www.amgentrials.com","http://www.vectibix.com/"]},"adverseEventsSummary":{"seriousAny":{"events":101,"n":229},"commonTop":["ERYTHEMA","PRURITUS","DERMATITIS ACNEIFORM","ANOREXIA","FATIGUE"]}}